This study demonstrated that the combined biomarker of APOBEC3B and CD274 was more effective in predicting the response to PD-1/PD-L1 inhibitors than a single biomarker of CD274 in bladder urothelial carcinoma. This evidence concerns the gene CD274 and bladder transitional cell carcinoma.